{"groups":[{"description":"Subjects will undergo mobilization and collection of HPC, Apheresis for subsequent use in various clinical protocols.\n\nFilgrastim: Filgrastim will be administered as a single daily dose in a dose range of 10-16ug/kg/day subcutaneously for 5-7days\n\nPlerixafor: Plerixafor will be given on day 4, 8-10 hours before the day 5 apheresis, dose calculated according to patient weight\n\nApheresis: The minimum cluster of differentiation 34 (CD34)+ cell dose that must be collected in order to proceed with a single autologous transplantation is 2 x 10\\^6 CD34+ cells/kg.","id":"FG000","title":"Hematopoietic Progenitor Cells (HPC)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"49"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"49"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Our study was a relatively small pilot study, with the primary emphasis being on expanding standard stem cell therapy options for patients with multiple myeloma. The plerixafor plus G-CSF combination is used relatively ubiquitously, and several larger studies relating to plerixafor have been performed at large centers that treat multiple myeloma."}